The trial will test four dose levels and include up to 18 patients with advanced, FLT3-expressing acute myeloid leukemia.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback